Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, to add to its balance sheet. This announcement follows the coin reaching a new all-time high of $808. Previously, the company had raised about $200 million for BNB purchases and is now seeking an additional $520 million through a $500 million equity line of credit and a $20 million stock purchase agreement. Windtree aims to boost its capital by utilizing a partnership with Kraken for custody. The company's stock has seen positive movement, rising by 162% over the past month. This move follows a trend among publicly traded companies, like MicroStrategy, that are investing in cryptocurrencies to enhance shareholder value.

Source đź”—